Sarah T Diepstraten, Yin Yuan, John E La Marca, Savannah Young, Catherine Chang, Lauren Whelan, Aisling M Ross, Karla C Fischer, Giovanna Pomilio, Rhiannon Morris, Angela Georgiou, Veronique Litalien, Fiona C Brown, Andrew W Roberts, Andreas Strasser, Andrew H Wei, Gemma L Kelly
TP53-mutant blood cancers remain a clinical challenge. BH3-mimetic drugs inhibit BCL-2 pro-survival proteins, inducing cancer cell apoptosis. Despite acting downstream of p53, functional p53 is required for maximal cancer cell killing by BH3-mimetics through an unknown mechanism. Here, we report p53 is activated following BH3-mimetic induced mitochondrial outer membrane permeabilization, leading to BH3-only protein induction and thereby potentiating the pro-apoptotic signal. TP53-deficient lymphomas lack this feedforward loop, providing opportunities for survival and disease relapse after BH3-mimetic treatment...
April 23, 2024: Cancer Cell